Puerarin Mitigates Diabetic Hepatic Steatosis and Fibrosis by Inhibiting TGF-β Signaling Pathway Activation in Type 2 Diabetic Rats
Joint Authors
Du, Guan-Hua
Xu, Chunyang
Hou, Biyu
Yang, Xiuying
Zhang, Li
Qiang, Guifen
Zhao, Yuerong
Chen, Xi
Liu, Chenge
Wang, Xiaobo
Source
Oxidative Medicine and Cellular Longevity
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-07-02
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
Lipid metabolism disorder and inflammation are essential promoters in pathogenesis of liver injury in type 2 diabetes.
Puerarin (PUR) has been reported to exert beneficial effects on many diabetic cardiovascular diseases and chemical-induced liver injuries, but its effects on diabetic liver injury and its mechanism are still unclear.
The current study was designed to explore the therapeutic effect and mechanism of PUR on liver injury in a type 2 diabetic rat model induced by a high-fat diet combined with low-dose streptozotocin.
The diabetic rats were treated with or without PUR (100 mg/kg/day) by gavaging for 8 weeks, and biochemical and histological changes in liver were examined.
Results showed that treatment with PUR significantly attenuated hepatic steatosis by regulating blood glucose and ameliorating lipid metabolism disorder.
Liver fibrosis was relieved by PUR treatment.
PUR inhibited oxidative stress and inflammation which was associated with inactivation of NF-κB signaling, thereby blocking the upregulation of proinflammatory cytokines (IL-1β, TNF-α) and chemokine (MCP-1).
This protection of PUR on diabetic liver injury is possibly related with inhibition on TGF-β/Smad signaling.
In conclusion, the present study provides evidence that PUR attenuated type 2 diabetic liver injury by inhibiting NF-κB-driven liver inflammation and the TGF-β/Smad signaling pathway.
American Psychological Association (APA)
Hou, Biyu& Zhao, Yuerong& Qiang, Guifen& Yang, Xiuying& Xu, Chunyang& Chen, Xi…[et al.]. 2018. Puerarin Mitigates Diabetic Hepatic Steatosis and Fibrosis by Inhibiting TGF-β Signaling Pathway Activation in Type 2 Diabetic Rats. Oxidative Medicine and Cellular Longevity،Vol. 2018, no. 2018, pp.1-13.
https://search.emarefa.net/detail/BIM-1211443
Modern Language Association (MLA)
Hou, Biyu…[et al.]. Puerarin Mitigates Diabetic Hepatic Steatosis and Fibrosis by Inhibiting TGF-β Signaling Pathway Activation in Type 2 Diabetic Rats. Oxidative Medicine and Cellular Longevity No. 2018 (2018), pp.1-13.
https://search.emarefa.net/detail/BIM-1211443
American Medical Association (AMA)
Hou, Biyu& Zhao, Yuerong& Qiang, Guifen& Yang, Xiuying& Xu, Chunyang& Chen, Xi…[et al.]. Puerarin Mitigates Diabetic Hepatic Steatosis and Fibrosis by Inhibiting TGF-β Signaling Pathway Activation in Type 2 Diabetic Rats. Oxidative Medicine and Cellular Longevity. 2018. Vol. 2018, no. 2018, pp.1-13.
https://search.emarefa.net/detail/BIM-1211443
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1211443